Based on the Akari Therapeutics PLC stock forecast from 0 analysts, the average analyst target price for Akari Therapeutics PLC is not available over the next 12 months. Akari Therapeutics PLC’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Akari Therapeutics PLC is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Akari Therapeutics PLC’s stock price was USD 1.15. Akari Therapeutics PLC’s stock price has changed by -18.43% over the past week, +18.19% over the past month and -60.07% over the last year.
No recent analyst target price found for Akari Therapeutics PLC
No recent average analyst rating found for Akari Therapeutics PLC
Company Overview Akari Therapeutics PLC
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts. Read Less
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic a...Read More
Frequently Asked Questions About Akari Therapeutics PLC (AKTX) Stock
Stock Target Advisor's fundamental analysis for Akari Therapeutics PLC's stock is Bearish.
Unfortunately we do not have enough data on AKTX's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on AKTX's stock to indicate what its average analyst target is.
AKTX stock's Price/Earning ratio is 10.00.
Our analysis grades AKTX stock's Price / Earning ratio at F. This means that AKTX stock's Price/Earning ratio is above 58.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this AKTX may be a overvalued for its sector.
The last closing price of AKTX's stock was USD 1.15.
The most recent market capitalization for AKTX is USD 0.03B.
Unfortunately we do not have enough analyst data on AKTX's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Akari Therapeutics PLC's stock.
As per our most recent records Akari Therapeutics PLC has 6 Employees.
Akari Therapeutics PLC's registered address is 22 Boston Wharf Road, Boston, MA, United States, 02210.
You can get more information about it from Akari Therapeutics PLC's website at https://www.akaritx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Akari Therapeutics PLC (AKTX) Stock
Stock Target Advisor's fundamental analysis for Akari Therapeutics PLC's stock is Bearish.
Unfortunately we do not have enough data on AKTX's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on AKTX's stock to indicate what its average analyst target is.
AKTX stock's Price/Earning ratio is 10.00.
Our analysis grades AKTX stock's Price / Earning ratio at F. This means that AKTX stock's Price/Earning ratio is above 58.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this AKTX may be a overvalued for its sector.
The last closing price of AKTX's stock was USD 1.15.
The most recent market capitalization for AKTX is USD 0.03B.
Unfortunately we do not have enough analyst data on AKTX's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Akari Therapeutics PLC's stock.
As per our most recent records Akari Therapeutics PLC has 6 Employees.
Akari Therapeutics PLC's registered address is 22 Boston Wharf Road, Boston, MA, United States, 02210.
You can get more information about it from Akari Therapeutics PLC's website at https://www.akaritx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AKTX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
